Since being FDA approved in 2012, Eliquis has become an excellent option for the prevention of stroke in patients with nonvalvular atrial fibrillation. Eliquis was approved based on the results of the 2011 ARISTOTLE Trial. During this trial, over 18,000 patients were studied. Eliquis was compared to Warfarin over a mean period of 1.8 years. During this study Eliquis was shown to be superior to Warfarin in reducing risk of stroke. Patients taking Eliquis also showed significantly less risk for major bleeding compared to Warfarin.